Posted in | News | Rare Earth Elements

Hudson Announces Phase 2 Results from ST1 Zone at Sarfartoq Rare Earth Element Project

HUDSON RESOURCES INC. (TSX VENTURE:HUD)(OTCQX:HUDRF) is pleased to provide drill results for the ST1 Zone from the Phase Two drilling program at the Sarfartoq Rare Earth Element Project in Western Greenland.

These additional three holes continued to intersect wide zones of high-grade rare earth elements with high ratios of neodymium. A total of 19 holes totaling 4,700m have been drilled into the ST1 Zone.

Highlights from the ST1 Zone:

In addition to the ST1 drilling program, the Company collected 17 channel samples and 26 outcrop/subcrop samples from the ST1 Zone. The channel samples, which covered 34m, average 1.72% total rare earth oxides (TREO). The other 26 outcrop/subcrop samples average 2.36% TREO. Four samples located 300m northeast of the main ST1 area average 5.5% TREO. These assays collected from surface samples of the ST1 Zone and the assays of the additional five holes drilled into ST1 will significantly contribute to building the 43-101 resource model, which is expected to be completed before year end.

James Tuer, Hudson's President, stated, "We are very pleased with these results as they continue to demonstrate the continuity and grade of the ST1 Zone and will be important additions to our first 43-101 resource model which is expected to be completed by the end of the year. The ST1 Zone continues to demonstrate that it contains significant REEs and elevated neodymium levels between 20-30%, which are some of the highest ratios in the industry. This is an important benefit of our project as neodymium is the key driver in the rare earth industry. We are also looking forward to receiving the remaining assays from the Phase Two drill program, which cover several high priority targets at the ST19 and ST24 zones. These results are expected to be released within the next 10 days."

The Company is currently undertaking additional mineralogical work on the 2010 drill results in order to select material for metallurgical testwork slated to commence next month. Mineralogical work conducted by Dr. Peter Le Couteur suggests that the rare earths in the ST1 Zone are present in carbonatite as the REE-fluorocarbonate minerals bastnasite-(Ce), synchysite-(Ce), synchysite-(Nd) and minor monazite-(Ce). Bastnasite is the principal ore mineral at the Mountain Pass REE Mine in California.

Drill core is logged and sampled in the field and split core is shipped to Vancouver for processing at ALS Chemex. A strict QA/QC program is followed, which includes the use of elemental standards, duplicates and blanks. In cases where the entire hole has not been sampled, only significant drill intersections of carbonate mineralization were sampled. Core was split in the field with half of the core being sent to ALS Chemex and the remaining half left on-site for future reference. All samples are analyzed using lithium borate fusion, acid dissolution and ICP-MS analysis (ALS method ME-MS81h). According to ALS Chemex, this procedure solubilizes most minerals, including refractory species, and provides the most quantitative analysis for many elements, including the rare earth elements.

The Sarfartoq REE project is located within 20 km of tidewater and only 60 km from Greenland's international airport. The project is owned 100% by Hudson. The Company is well financed with current working capital of approximately $3.5 million and sufficient funds to cover all exploration and G&A obligations into 2011.

Dr. Michael Druecker is a qualified person as defined by National Instrument 43-101 and reviewed the preparation of the scientific and technical information in this press release in respect of the Sarfartoq REE Project.

Source: HUDSON RESOURCES INC.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.